Nutex Health Inc NUTX Stock Analysis
- Nasdaq
- Stock
- Market closed · opens Monday 9:30 AM ET
$180.56 down $13.08, 6.75% at close Nov 6
Last close · Previous close $193.64
- Market cap
- $1.24BAt the Nov 6 close
- P/E ratio
- 7.15On last 12 months’ EPS
- Diluted EPS
- $25.27Last 12 months
- Dividend yield
- NoneLast 12 months
Price chart
$180.56down $13.08, 6.75%Fri, Nov 6 session
Use the left and right arrow keys to move along the chart.
Price data
Trading
- Previous close$193.64Nov 5
- Volume168.32KNov 6 session
Shares traded on all US exchanges in the last completed session. Live intraday volume covers IEX only, so it is left out.
- Avg. volume138.19KLast 21 sessions
The average daily shares traded over the last 21 trading sessions, about one calendar month.
- 52-week range: $83.99 to $226.16; now $180.56
The lowest and highest trades over the past 52 weeks, adjusted for splits. The marker shows the latest price.
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
Performance
Past performance, measured to the Nov 6 close. Total return includes reinvested dividends.Price change only, without dividends. Compared with the S&P 500, using SPY.
NUTX beat the S&P 500 in 4 of 7 periods.
| Period | NUTX and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | NUTX: down 17.3% S&P 500: down 5.6% | NUTX trailed the S&P 500 by 11.7 percentage points Trailed |
| 3M | NUTX: up 18.8% S&P 500: down 4.1% | NUTX beat the S&P 500 by 22.9 percentage points Beat |
| YTD | NUTX: up 9.7% S&P 500: up 8.7% | NUTX beat the S&P 500 by 1.0 percentage points Beat |
| 1Y | NUTX: up 48.3% S&P 500: up 10.9% | NUTX beat the S&P 500 by 37.4 percentage points Beat |
| Long term | ||
| 3Y | NUTX: up 361.9% S&P 500: up 75.0% +66.5% vs +20.5% a year | NUTX beat the S&P 500 by 286.9 percentage points Beat |
| 5Y | NUTX: down 69.9% S&P 500: up 67.8% −21.4% vs +10.9% a year | NUTX trailed the S&P 500 by 137.7 percentage points Trailed |
| 10Y | NUTX: down 96.3% S&P 500: up 313.1% −28.1% vs +15.2% a year | NUTX trailed the S&P 500 by 409.4 percentage points Trailed |
$10,000 invested in NUTX 10 years ago (Nov 4, 2016) would be worth about $370 at the close on , with dividends reinvested. The same amount in the S&P 500 would be worth about $41,313.
NUTX beat the S&P 500 in 4 of 7 periods.
| Period | NUTX and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | NUTX: down 17.3% S&P 500: down 5.6% | NUTX trailed the S&P 500 by 11.7 percentage points Trailed |
| 3M | NUTX: up 18.8% S&P 500: down 4.3% | NUTX beat the S&P 500 by 23.1 percentage points Beat |
| YTD | NUTX: up 9.7% S&P 500: up 7.8% | NUTX beat the S&P 500 by 1.9 percentage points Beat |
| 1Y | NUTX: up 48.3% S&P 500: up 9.7% | NUTX beat the S&P 500 by 38.6 percentage points Beat |
| Long term | ||
| 3Y | NUTX: up 361.9% S&P 500: up 68.8% +66.5% vs +19.1% a year | NUTX beat the S&P 500 by 293.1 percentage points Beat |
| 5Y | NUTX: down 69.9% S&P 500: up 56.9% −21.4% vs +9.4% a year | NUTX trailed the S&P 500 by 126.8 percentage points Trailed |
| 10Y | NUTX: down 96.3% S&P 500: up 252.6% −28.1% vs +13.4% a year | NUTX trailed the S&P 500 by 348.9 percentage points Trailed |
$10,000 invested in NUTX 10 years ago (Nov 4, 2016) would be worth about $370 at the close on , not counting dividends. The same amount in the S&P 500 would be worth about $35,257.
All-time high
$56,250.00
Closing high on . Now 99.7% below that record.
Split-adjusted daily closes since Apr 8, 2013.
Stock splits
3
Latest: 1-for-10 on . Share counts adjust after each split.
All 3 splits
- 1-for-10
- 1-for-15
- 1-for-500
Valuation
The Nov 6 close compared with the last 12 months of reported results (the four quarters to Jun 30, 2026). Tap a metric to see how it’s calculated.
Price-to-earnings (P/E)
7.1×The Nov 6 close ÷ diluted EPS over the last 12 months ($25.27)
The range covers daily P/E ratios from Oct 28, 2021 to Nov 6, 2026, each based on the previous 12 months of earnings.
NUTX trades at 7.1× its earnings over the last 12 months, below its 5-year median of 7.6×. In plain terms, buyers are paying about $7 for each $1 of profit from the past year. How to read P/E
Other valuation measures
- 1.5×Last 12 months’ revenue
Market value divided by revenue over the last 12 months. Useful when earnings are small or negative.
P/S = Market cap ÷ Revenue (last 12 months)Price-to-sales ratio - 3.2×Book value as of Jun 30, 2026
Price relative to accounting equity (book value) per share on the Jun 30, 2026 balance sheet. Asset-light companies often trade far above book value.
P/B = Price ÷ Book value per sharePrice-to-book ratio - 4.7×Last 12 months’ EBITDA
Enterprise value divided by EBITDA over the last 12 months. It compares companies with different amounts of debt.
EV/EBITDA = Enterprise value ÷ EBITDA (last 12 months)EV/EBITDA explained - 0.05Last 12 months’ EPS growth
The P/E divided by the growth in diluted EPS over the last 12 months (+146.3% on the 12 months before). It looks backward: near 1 means the P/E roughly matches last year’s growth. Sites that use analysts’ growth forecasts show a different PEG.
PEG = P/E ÷ EPS growth (%) = 7.1 ÷ 146.3 - 22.07%Last 12 months’ free cash flow
Free cash flow over the last 12 months as a share of the company’s market value: the cash the business generated for each dollar of stock.
FCF yield = Free cash flow (last 12 months) ÷ Market capFree cash flow - $1.38BAt the Nov 6 close
What it would cost to buy the whole business: the market cap at the Nov 6 close, plus debt, minus cash and short-term investments from the Jun 30, 2026 balance sheet.
EV = Market cap + Debt − Cash and short-term investmentsEV/EBITDA explained
Build your own NUTX DCF in Excel. Value Nutex Health with your own growth and margin assumptions.Browse DCF models Free DCF calculator
Financials
Reported results, not forecasts. From company filings via Tiingo; the latest report is Q2 FY26, the quarter ended Jun 30, 2026. “Last 12 months” means the four quarters from Jul 1, 2025 to Jun 30, 2026, and balance-sheet figures are as of Jun 30, 2026.
Revenue and net income
Last 12 months, with the change from the 12 months before
- Revenue
- $846.72Mup 6.9%
- Net income
- $179.92Mup 219.3%
- Diluted EPS
- $25.27up 146.3%
Data table
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| Q3 FY24 (Sep 30, 2024) | $78.80M | −$8.79M | −$1.72 |
| Q4 FY24 (Dec 31, 2024) | $257.62M | $61.61M | $11.60 |
| Q1 FY25 (Mar 31, 2025) | $211.79M | $21.22M | $3.33 |
| Q2 FY25 (Jun 30, 2025) | $243.99M | −$17.70M | −$2.95 |
| Q3 FY25 (Sep 30, 2025) | $267.80M | $55.44M | $7.76 |
| Q4 FY25 (Dec 31, 2025) | $151.68M | $11.83M | $1.61 |
| Q1 FY26 (Mar 31, 2026) | $216.49M | $46.81M | $6.52 |
| Q2 FY26 (Jun 30, 2026) | $210.75M | $65.84M | $9.38 |
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| FY21 (Dec 31, 2021) | $331.53M | $132.59M | Paused See the note under the price. |
| FY22 (Dec 31, 2022) | $219.29M | −$424.78M | Paused See the note under the price. |
| FY23 (Dec 31, 2023) | $247.65M | −$45.79M | Paused See the note under the price. |
| FY24 (Dec 31, 2024) | $479.95M | $52.10M | $9.69 |
| FY25 (Dec 31, 2025) | $875.26M | $70.79M | $10.48 |
Margins
- Gross 51.3%
- Operating 43.0%
- Net 21.2%
The percentages above the chart cover the last 12 months; the lines show each quarter. What margins tell you
Cash flow
- $274.17MLast 12 months
Cash from operations minus capital spending: the cash left after the business maintains and grows its assets.
FCF = Operating cash flow − Capital spendingFree cash flow - Operating cash flow$279.62MLast 12 months
- Capital spending$5.45MLast 12 months
- 32.4%Last 12 months
Free cash flow as a share of revenue, both over the last 12 months.
Shareholder returns
- $55.61MLast 12 months
Cash spent repurchasing shares, net of shares issued. Buybacks shrink the share count, so each remaining share owns more of the company.
- Dividends paid$0.00Last 12 months
- Total returned$55.61MLast 12 months
20% of free cash flow
Balance sheet
- $207.11MAs of Jun 30, 2026
Cash plus short- and long-term marketable securities on the Jun 30, 2026 balance sheet.
- Total debt$347.34MAs of Jun 30, 2026
- Net debt$140.23MAs of Jun 30, 2026
- 5.00As of Jun 30, 2026
Current assets divided by current liabilities on the Jun 30, 2026 balance sheet. Above 1 means short-term assets cover the bills due within a year.
Current ratio = Current assets ÷ Current liabilitiesCurrent ratio - 0.88As of Jun 30, 2026
Total debt divided by shareholders’ equity on the Jun 30, 2026 balance sheet: a measure of financial leverage.
D/E = Total debt ÷ Shareholders’ equityDebt-to-equity ratio
Financial strength
- 6 of 9Last 12 months
vs the 12 beforeA 0–9 checklist from accounting professor Joseph Piotroski. Each test compares the last 12 months with the 12 months before and scores a point if it passes. 8–9 is strong; 0–2 is weak.
- ✓Net income was positive: passed
- ✓Operating cash flow was positive: passed
- ✓Return on assets improved: passed
- ✓Operating cash flow exceeded net income: passed
- ✓Long-term debt fell relative to assets: passed
- ✓Current ratio improved: passed
- ✗Share count didn’t rise: not passed
- ✗Gross margin improved: not passed
- ✗Asset turnover (revenue ÷ assets) improved: not passed
- 51.9%Last 12 months
Over the last 12 months, Nutex Health’s net income was 51.9% of its shareholders’ equity (averaged over the last four quarter-ends). It describes the past year, not an expected return. ROE can run this high when equity is small, for example after years of large share buybacks.
ROE = Net income (last 12 months) ÷ Average equityReturn on equity - 18.9%Last 12 months
Over the last 12 months, Nutex Health’s net income was 18.9% of its total assets (averaged over the last four quarter-ends): what the business earned on everything it owns.
ROA = Net income (last 12 months) ÷ Average total assets
About Nutex Health Inc
Headquartered in Houston, Texas, Nutex Health Inc. (NASDAQ and Nasdaq Texas: NUTX) is a physician-led, healthcare services and operations company with three divisions: a Hospital Division, a Population Health Management Division, and a Real Estate Division. The Hospital Division owns, develops, and operates innovative health care models, including micro-hospitals, specialty hospitals, and hospital outpatient departments. This division owns and operates 28 hospital facilities in 12 states. The Population Health Management Division owns and operates provider networks such as Independent Physician Associations. Through our Management Services Organization, we provide management, administrative and other support services to our affiliated hospitals and physician groups. The Real Estate division comprises of real estate entities along with activity related to the development and construction of hospital facilities. The real estate entities own the land and hospital buildings which are leased to our hospital entities.
- Sector
- Healthcare
- Industry
- Health Information Services
- Headquarters
- Florida, USA
- SEC filings
- EDGAR (opens in a new tab)
- Exchange
- Nasdaq
- Asset type
- Common stock
- Price history since
NUTX news
Explore more stocks
Prices are from the last refresh. Open any stock for its live dashboard.
Popular stocks
NUTX stock FAQ
What is NUTX stock’s price today?
Nutex Health (NUTX) traded at $180.56 at the close on , down $13.08 (6.75%) from the previous close of $193.64. Over the past 52 weeks it has traded between $83.99 and $226.16.
If you invested $1,000 in NUTX 10 years ago, how much would you have now?
With dividends reinvested, $1,000 invested in NUTX on would be worth about $37 at the close on , a total return of −96.3%. The same $1,000 would be worth $301 if invested five years ago and $1,483 if invested one year ago. Past performance doesn’t predict future returns.
What is Nutex Health’s market cap?
Nutex Health’s market capitalization is about $1.2 billion. That’s Tiingo’s daily market cap for , at that day’s closing price of $180.56 (how market cap works). Nutex Health reported 6.88M shares outstanding at the end of its latest quarter ().
What is NUTX’s P/E ratio?
NUTX trades at 7.1 times its diluted earnings over the four quarters to ($25.27 per share), at the close. Over the past five years its P/E has ranged from 0.7 to 39.9, with a median of 7.6. (How the P/E ratio works.)
How much revenue does Nutex Health make?
Nutex Health reported $846.7 million of revenue over the four quarters to , up 6.9% from the twelve months before. In its latest quarter (Q2 FY26, ended ) revenue was $210.8 million, down 13.6% from a year earlier.
Is Nutex Health profitable?
Yes. Nutex Health earned $179.9 million of net income over the four quarters to , a net margin of 21.2%, and its operating margin was 43.0% (what margins tell you).
What are NUTX’s earnings per share?
NUTX’s diluted earnings per share were $25.27 over the four quarters to , compared with $10.26 in the twelve months before. The latest quarter (Q2 FY26) brought $9.38 per share, against −$2.95 a year earlier (how EPS works).
Does NUTX pay a dividend?
Nutex Health hasn’t paid a dividend in the last twelve months.
What is NUTX’s 52-week high and low?
Over the past 52 weeks NUTX has traded as low as $83.99 and as high as $226.16. At $180.56 at the close on , it is 20.2% below that high and 115.0% above the low.
What is NUTX’s all-time high?
NUTX’s highest closing price was $56,250.00 on , adjusted for stock splits. At $180.56 at the close on , it is 99.7% below that record.
Has NUTX stock ever split?
Yes, three times: 1-for-500 on ; 1-for-15 on ; 1-for-10 on .
How has NUTX stock performed?
Including dividends and measured to the close on , NUTX has returned +9.7% so far this year and +48.3% over the past year, and −69.9% over five years (−21.4% a year). Over the same periods the S&P 500, measured by SPY, returned +8.7%, +10.9% and +67.8%. Past performance doesn’t predict future returns.
What sector and industry is Nutex Health in?
Nutex Health is in the Healthcare sector and the Health Information Services industry, and is headquartered in Florida, USA.
What exchange does NUTX trade on?
Nutex Health trades on the Nasdaq under the ticker symbol NUTX. Its price history on this dashboard begins on .
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
About this data. Data sourced by Tiingo (opens in a new tab). The live price is Tiingo’s real-time price, based on IEX trades and quotes; intraday charts show IEX trades, and volume figures are consolidated totals for completed sessions. Prices are split-adjusted, and total returns assume dividends are reinvested. Financials come from company filings and can lag new reports. Times are Eastern.
This page is for education, not investment advice. Past performance doesn't predict future returns. Logos provided by Logo.dev (opens in a new tab).
The Interactive Brokers word and logo are trademarks of Interactive Brokers LLC (or its subsidiaries) in the US and/or elsewhere. All rights reserved.